Skip to content
Home/Companies/Biotech/Prosion
Prosion

Prosion

Biotech·Germany·Active·4yr hold
Entry
2022
Hold
4yr
Status
Active

Who owns Prosion?

Prosion is a German Biotech company, currently owned by Freigeist Capital since 2022.

Hand-verified · updated 2026-07-03

Open JSON · CC-BY
Freigeist Capital
Investor
Freigeist Capital
Freigeist Deep-Tech Evergreen · 2017 · Evergreen

Key facts

HQGermany
SectorBiotech
StatusActive
Websitewww.prosion.eu

More from Freigeist Deep-Tech Evergreen

Other portfolio companies in the same fund.

Zahnheld
Active
Germany· 2026
Akina
Akina
Active
MedTechSwitzerland· 2025
Collie
Collie
Active
SoftwareGermany· 2025
BioThrust
Active
BiotechGermany· 2024
United Manufacturing Hub
Active
SoftwareGermany· 2024
Leko Labs
Active
ConstructionLuxembourg· 2022

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS

Questions

Who owns Prosion?

Prosion is currently owned by Freigeist Capital, through Freigeist Deep-Tech Evergreen, since 2022.

When did Freigeist Capital acquire Prosion?

Freigeist Capital acquired Prosion in 2022.

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue